Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Regårdh CG[au]:

Search results

Items: 1 to 50 of 114

1.

Selective downregulation of the MDR1 gene product in Caco-2 cells by stable transfection to prove its relevance in secretory drug transport.

Hilgendorf C, Spahn-Langguth H, Rhedin M, Regårdh CG, Löwenadler B, Langguth P.

Mol Pharm. 2005 Jan-Feb;2(1):64-73.

PMID:
15804179
2.

Enantioselective pharmacokinetics of the enantiomers of clevidipine following intravenous infusion of the racemate in essential hypertensive patients.

Ericsson H, Schwieler J, Lindmark BO, Löfdahl P, Thulin T, Regårdh CG.

Chirality. 2001;13(3):130-4.

PMID:
11270321
3.

Pharmacokinetics and arteriovenous differences in clevidipine concentration following a short- and a long-term intravenous infusion in healthy volunteers.

Ericsson H, Bredberg U, Eriksson U, Jolin-Mellgård A, Nordlander M, Regårdh CG.

Anesthesiology. 2000 Apr;92(4):993-1001.

PMID:
10754618
4.

Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: drugs and analogs, stereoisomers and metabolites.

Neuhoff S, Langguth P, Dressler C, Andersson TB, Regårdh CG, Spahn-Langguth H.

Int J Clin Pharmacol Ther. 2000 Apr;38(4):168-79.

PMID:
10783826
5.

Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport.

Hilgendorf C, Spahn-Langguth H, Regårdh CG, Lipka E, Amidon GL, Langguth P.

J Pharm Sci. 2000 Jan;89(1):63-75.

PMID:
10664539
6.
7.

Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers.

Ericsson H, Fakt C, Jolin-Mellgård A, Nordlander M, Sohtell L, Sunzel M, Regårdh CG.

Br J Clin Pharmacol. 1999 May;47(5):531-8.

8.

Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs.

Ericsson H, Tholander B, Björkman JA, Nordlander M, Regårdh CG.

Drug Metab Dispos. 1999 May;27(5):558-64.

PMID:
10220482
9.

Pharmacokinetics and pharmacodynamics of clevidipine in healthy volunteers after intravenous infusion.

Ericsson H, Fakt C, Höglund L, Jolin-Mellgård A, Nordlander M, Sunzel M, Regårdh CG.

Eur J Clin Pharmacol. 1999 Mar;55(1):61-7.

PMID:
10206087
11.

Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay.

Döppenschmitt S, Langguth P, Regårdh CG, Andersson TB, Hilgendorf C, Spahn-Langguth H.

J Pharmacol Exp Ther. 1999 Jan;288(1):348-57.

PMID:
9862789
12.
13.

The interaction effect of grapefruit juice is maximal after the first glass.

Lundahl JU, Regårdh CG, Edgar B, Johnsson G.

Eur J Clin Pharmacol. 1998 Mar;54(1):75-81.

PMID:
9591935
14.

Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an antithrombotic drug.

Eriksson UG, Renberg L, Bredberg U, Teger-Nilsson AC, Regårdh CG.

Biopharm Drug Dispos. 1998 Jan;19(1):55-64.

PMID:
9510985
15.
16.
17.

Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals.

Ishizaki T, Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, Andersson T, Regårdh CG, Lou YC, Zhang Y, et al.

Ther Drug Monit. 1994 Apr;16(2):214-5.

PMID:
8009572
18.

Central nervous and systemic kinetics of ramipril and ramiprilat in the conscious dog.

Nordström M, Abrahamsson T, Ervik M, Forshult E, Regårdh CG.

J Pharmacol Exp Ther. 1993 Jul;266(1):147-52.

PMID:
8331554
20.
21.
22.

Pharmacokinetics of [14C]omeprazole in patients with liver cirrhosis.

Andersson T, Olsson R, Regårdh CG, Skånberg I.

Clin Pharmacokinet. 1993 Jan;24(1):71-8.

PMID:
8448974
24.

Pharmacokinetic study of omeprazole in elderly healthy volunteers.

Landahl S, Andersson T, Larsson M, Lernfeldt B, Lundborg P, Regårdh CG, Sixt E, Skånberg I.

Clin Pharmacokinet. 1992 Dec;23(6):469-76.

PMID:
1458764
25.

The effect of felodipine on bile flow in pentobarbital anaesthetized rats and conscious rats receiving bile salt supplementation.

Wang SX, Sutfin TA, Regårdh CG.

Eur J Drug Metab Pharmacokinet. 1992 Oct-Dec;17(4):263-8.

PMID:
1301355
26.

Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice.

Miniscalco A, Lundahl J, Regårdh CG, Edgar B, Eriksson UG.

J Pharmacol Exp Ther. 1992 Jun;261(3):1195-9.

PMID:
1602384
27.

Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects.

Andersson T, Regårdh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L.

Pharmacogenetics. 1992 Feb;2(1):25-31.

PMID:
1302040
28.

Determination of four carboxylic acid metabolites of felodipine in plasma by high-performance liquid chromatography.

Gabrielsson M, Hoffmann KJ, Regårdh CG.

J Chromatogr. 1992 Jan 17;573(2):265-74.

PMID:
1601959
29.

Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance.

Edgar B, Bailey D, Bergstrand R, Johnsson G, Regårdh CG.

Eur J Clin Pharmacol. 1992;42(3):313-7.

PMID:
1577050
30.

Stereoselective metabolism of felodipine in liver microsomes from rat, dog, and human.

Eriksson UG, Lundahl J, Bäärnhielm C, Regårdh CG.

Drug Metab Dispos. 1991 Sep-Oct;19(5):889-94.

PMID:
1686232
31.

Pharmacokinetics of felodipine in chronic hemodialysis patients.

Buur T, Larsson R, Regårdh CG, Aberg J.

J Clin Pharmacol. 1991 Aug;31(8):709-13.

PMID:
1880229
32.

Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol.

Andersson T, Lundborg P, Regårdh CG.

Eur J Clin Pharmacol. 1991;40(1):61-5.

PMID:
2060547
33.

Pharmacokinetics of the enantiomers of felodipine in the dog after oral and intravenous administration of a pseudoracemic mixture.

Eriksson UG, Hoffmann KJ, Simonsson R, Regårdh CG.

Xenobiotica. 1991 Jan;21(1):75-84.

PMID:
2003369
34.

Pharmacokinetics of a single intravenous and oral dose of pafenolol--a beta 1-adrenoceptor antagonist with atypical absorption and disposition properties--in man.

Regårdh CG, Lundborg P, Gabrielsson M, Heggelund A, Kylberg-Hanssen K.

Pharm Res. 1990 Dec;7(12):1222-7.

PMID:
1982773
35.

Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function.

Larsson R, Karlberg BE, Gelin A, Aberg J, Regårdh CG.

J Clin Pharmacol. 1990 Nov;30(11):1020-30.

PMID:
2243149
37.

Pharmacokinetics of pafenolol after i.v. and oral administration of three separate doses of different strength to man.

Regardh CG, Heggelund A, Kylberg-Hanssen K, Lundborg P.

Biopharm Drug Dispos. 1990 Oct;11(7):607-17.

PMID:
1979923
38.

Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators.

Andersson T, Regårdh CG, Dahl-Puustinen ML, Bertilsson L.

Ther Drug Monit. 1990 Jul;12(4):415-6. No abstract available.

PMID:
2396316
39.

The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses.

Regårdh CG, Andersson T, Lagerström PO, Lundborg P, Skånberg I.

Ther Drug Monit. 1990 Mar;12(2):163-72.

PMID:
2315973
40.

Pharmacokinetic and biopharmaceutic aspects of once daily treatment with metoprolol CR/ZOK: a review article.

Sandberg A, Abrahamsson B, Regårdh CG, Wieselgren I, Bergstrand R.

J Clin Pharmacol. 1990 Feb;30(S2):S2-16. Review.

PMID:
2179280
41.

The relationship between metoprolol plasma concentration and beta 1-blockade in healthy subjects: a study on conventional metoprolol and metoprolol CR/ZOK formulations.

Abrahamsson B, Lücker P, Olofsson B, Regårdh CG, Sandberg A, Wieselgren I, Bergstrand R.

J Clin Pharmacol. 1990 Feb;30(S2):S46-54.

PMID:
1968913
42.

Biliary secretion of felodipine metabolites in man after intravenous [14C]felodipine.

Sutfin TA, Lind T, Gabrielsson M, Regårdh CG.

Eur J Clin Pharmacol. 1990;38(5):421-4.

PMID:
2379526
43.

The rhesus monkey as a model for studies of pregnancy induced changes in metoprolol metabolism.

Högstedt S, Lindberg BS, Regårdh CG, Moström U, Rane A.

Pharmacol Toxicol. 1990 Jan;66(1):32-6.

PMID:
2308905
44.

Pharmacokinetics of various single intravenous and oral doses of omeprazole.

Andersson T, Cederberg C, Regårdh CG, Skånberg I.

Eur J Clin Pharmacol. 1990;39(2):195-7.

PMID:
2253676
45.

Pharmacokinetic and pharmacodynamic properties of atenolol in acute myocardial infarction.

Held P, Regårdh CG, Swedberg K.

J Cardiovasc Pharmacol. 1990 Jan;15(1):172-4.

PMID:
1688977
46.

Contribution of the intestine to the first-pass metabolism of felodipine in the rat.

Wang SX, Sutfin TA, Bäärnhielm C, Regårdh CG.

J Pharmacol Exp Ther. 1989 Aug;250(2):632-6.

PMID:
2760845
47.

Pharmacokinetics of felodipine in patients with liver disease.

Regårdh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C.

Eur J Clin Pharmacol. 1989;36(5):473-9.

PMID:
2753065
48.

Pharmacokinetics of felodipine in patients with impaired renal function.

Edgar B, Regårdh CG, Attman PO, Aurell M, Herlitz H, Johnsson G.

Br J Clin Pharmacol. 1989 Jan;27(1):67-74.

49.

Central nervous system kinetics of atenolol and metoprolol in the dog during long term treatment.

Abrahamsson T, Lignell E, Mikulski A, Olovson SG, Regårdh CG.

Drug Metab Dispos. 1989 Jan-Feb;17(1):82-6.

PMID:
2566475
50.

Binding of the beta-blockers timolol and H 216/44 to ocular melanin.

Abrahamsson T, Boström S, Bräutigam J, Lagerström PO, Regårdh CG, Vauqelin G.

Exp Eye Res. 1988 Oct;47(4):565-77.

PMID:
2903066

Supplemental Content

Loading ...
Support Center